Searched for
INTERNATIONAL PATIENT REVENUE
Entrepreneurship and innovation: Scaling India's strategic technology ecosystemIndia's pursuit of technological self-reliance is gathering pace as sovereign capabilities in defence, space, semiconductors, and secure co...- Healthcare demand is outstripping supply in Noida, says MOFSL; prefers Medanta, Max HealthcareNoida-Greater Noida is rapidly becoming a prime healthcare hub in North India, fueled by population growth and corporate expansion. Despite...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- Noel exiting Trent: The quiet Tata who built a loud success storyNoel Tata reportedly told shareholders at Trent's annual general meeting that it would be his last as chairman, signalling the close of a t...
- Palestinian Embassy calls for urgent medical aid: "If not India and Indian people, then who?"Palestine's Embassy in India has issued a dire plea for immediate medical aid, warning of a healthcare sector collapse due to ongoing confl...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Public-private projects key to expand access to Kidney care: NephroPlusNephroPlus, India's leading provider of dialysis services, is on a mission to reshape the future of kidney health with an innovative tech-b...
- ETMarkets Smart Talk | Defence and electrification are multi-year structural themes for India: Prateek AgrawalGeopolitical shifts and the drive for self-reliance are creating long-term investment opportunities in India's defence and electrification ...
- Manipur CM urges NITI Aayog to drive state's recovery and developmentManipur Chief Minister Yumnam Khemchand Singh urged NITI Aayog to spearhead the state's economic recovery and long-term development, emphas...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- West Bengal's electronics factory push; Fed jitters hit TCSWest Bengal is exploring ways to expand electronics manufacturing under EMC 2.0. This and more in today's ETtech Top 5.
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Lebanon ceasefire raises hopes of progress for Iran dealIsrael and Lebanon have agreed to a ceasefire brokered by the United States. This development offers hope for de-escalation in the ongoing ...
- PE wars to billion-dollar IPO dreams, hospital sector is fighting fitMajor private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition high...
- 'Wait out IT, buy pharma and defence'; Ajay Bagga's 3-sector playbook for 2026Ajay Bagga offers a clear strategy for Indian markets. He advises waiting for real AI revenue in IT. Pharma remains a strong investment due...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studiesGSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achievi...
- Max Healthcare Q4 results: Cons PAT grows 7% YoY to Rs 342 crore, revenue rises 12%Max Healthcare Q4FY26 consolidated PAT grew 7% YoY, and revenue increased 12%. Network EBITDA rose 8%. Max Lab and Max@Home saw strong doub...
Load More
